Enlivex Therapeutics Stock Revenue
| ENLV Stock | ILA 415.10 4.10 0.98% |
Enlivex Therapeutics fundamentals help investors to digest information that contributes to Enlivex Therapeutics' financial success or failures. It also enables traders to predict the movement of Enlivex Stock. The fundamental analysis module provides a way to measure Enlivex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Enlivex Therapeutics stock.
Enlivex |
Enlivex Therapeutics Company Revenue Analysis
Enlivex Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Enlivex Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The revenue for all Israel stocks is 100.0% higher than that of the company.
Enlivex Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Enlivex Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Enlivex Therapeutics could also be used in its relative valuation, which is a method of valuing Enlivex Therapeutics by comparing valuation metrics of similar companies.Enlivex Therapeutics is currently under evaluation in revenue category among its peers.
Enlivex Fundamentals
| Return On Equity | -0.38 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 147.66 M | |||
| Shares Outstanding | 18.41 M | |||
| Shares Owned By Insiders | 12.19 % | |||
| Shares Owned By Institutions | 9.53 % | |||
| Price To Book | 1.23 X | |||
| EBITDA | (18.74 M) | |||
| Net Income | (14.47 M) | |||
| Cash And Equivalents | 90.6 M | |||
| Cash Per Share | 4.95 X | |||
| Total Debt | 615 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 20.29 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (17.54 M) | |||
| Earnings Per Share | (1.07) X | |||
| Number Of Employees | 71 | |||
| Beta | 0.61 | |||
| Market Capitalization | 273.23 M | |||
| Total Asset | 95.15 M | |||
| Net Asset | 95.15 M |
About Enlivex Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Enlivex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enlivex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enlivex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Enlivex Stock
When determining whether Enlivex Therapeutics is a strong investment it is important to analyze Enlivex Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Enlivex Therapeutics' future performance. For an informed investment choice regarding Enlivex Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enlivex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Enlivex Stock refer to our How to Trade Enlivex Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.